Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human PD-L1 / B7-H1 Protein (HPLC-verified), His tag, 100µg  

Recombinant Human PD-L1 / B7-H1 Protein (HPLC-verified), His tag, 100µg

Recombinant Human PD-L1 / B7-H1 Protein, Phe 19 - Arg 238, produced in human 293 cells (HEK293), (MALS verified), His tag

Synonym
recombinant human protein PD-L1,CD274,B7-H1,PDCD1L1,PDCD1LG1

More details

PD1-H5229-100

Availability: within 7 days

396,00 €

Background
Programmed cell death 1 ligand 1 (PD-L1) is also known as cluster of differentiation (CD274) or B7 homolog 1 (B7-H1), is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses. B7-H1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. PD-L1 is highly expressed in the heart, skeletal muscle, placenta and lung and weakly expressed in the thymus, spleen, kidney and liver. PD-L1 is expressed on activated T-cells, B-cells, dendritic cells, keratinocytes and monocytes. PD-L1 is up-regulated on T- and B-cells, dendritic cells, keratinocytes and monocytes after LPS and IFNG activation and up-regulated in B-cells activated by surface Ig cross-linking. PD-L1 involve in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner.

Source
Recombinant Human PD-L1, His Tag (PD1-H5229) is expressed from human 293 cells (HEK293). It contains AA Phe 19 - Arg 238 (Accession # NP_054862.1).
Predicted N-terminus: Phe 19

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 26.0 kDa. The protein migrates as 30-35 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg of the Human PD-L1, His Tag (HPLC-verified) by the LAL method.

Purity
>98% as determined by SDS-PAGE.
>90% as determined by SEC-HPLC.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization. 

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2"
Spirina, Yurmazov, Usynin et al
Curr Issues Mol Biol (2021) 43 (2), 1072-1080
(2) "Risk factors for Immune-related Adverse Events from anti-PD-1 or anti PD-L1 treatment in an Asian cohort of non-small cell lung cancer patients"
Huang, Soon, Aminkeng et al
Int J Cancer (2021)
(3) "Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model"
Zhang, Xie, Zhang et al
Cancer Gene Ther (2021)
Showing 1-3 of 16933 papers.
Please refer to product data sheet.

The following products could also be interesting for you: